Manas AI, which is founded by Reid Hoffman, a LinkedIn co-founder and partner at Greylock, along with renowned oncologist Dr. Siddhartha Mukherjee, announced today the close of $24.6 million seed funding. It has planned to revolutionize the way of finding a new drug to cure cancer with artificial intelligence.

Founders’ Vision

Reid Hoffman is a well-known tech investor and co-founder of LinkedIn. He teams up with Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and professor of medicine at Columbia University, to combine technological innovation with medical expertise. 

Dr. Mukherjee’s work in oncology has given him a deep understanding of cancer biology, which, when combined with advanced AI capabilities, holds the promise of accelerating the drug discovery process.

Read also: Scripta Insights Secures $17Mto Revolutionize Prescription Drug Shopping in America

The Future of Drug Discovery with Artificial Intelligence

AI in drug discovery is likely to overcome many of the issues associated with traditional approaches:

• Data Analysis: AI algorithms can process vast datasets, identifying patterns and potential drug targets more efficiently than manual analysis.
• Predictive Modeling: Machine learning models can predict how compounds will interact with biological targets, streamlining the identification of promising drug candidates.
• Accelerated Timelines: AI will cut the time needed to get new drugs from idea to clinical trials by automating parts of the research process.

Though promising, no approved drug has yet come out of the field, showing that AI predictions are far from easily translatable into clinically effective treatments. 

Strategic Partnerships and Infrastructure

Manas AI plans to use strategic partnerships to bolster its technological infrastructure:

• Microsoft Collaboration: Microsoft will run its AI systems inside Microsoft’s data centers. The company will avail advanced computational capacity and cloud infrastructure, hence, this collaboration is likely to be furthered by Reid Hoffman sitting on the board of Microsoft.
• Venture Capital Support: General Catalyst led this financing round. Greylock, which Hoffman has served as a general partner, also participated. This venture capital assistance is always much welcome because it can help raise sufficient funds for furthering research and development work.

Read also: Retro Biosciences Aims to Extend Human Lifespan with $1 Billion Funding Initiative

Future Directions

While the initial focus is set on specific cancers, Manas AI continues to foresee further expansion of its research in a broader set of diseases, such as autoimmune diseases and rare disease entities. Long term, the company envisions developing its own drugs and making them commercialized products, leveraging AI to streamline discovery and development process.